Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitroAlejandro Ibáñez‐Costa, Justo P. Castaño, Silvia Maraver-Selfa et al.|Journal of Endocrinology|2016Cited by 74
BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomasAlejandro Ibáñez‐Costa, Raúl M. Luque, Laura M. López‐Sánchez et al.|Scientific Reports|2017Cited by 32
Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH studyMiguel Sampedro‐Núñez, F. Comunas, Aura D. Herrera‐Martínez et al.|European Journal of Endocrinology|2024Cited by 7
Differential in vitro response to octreotide and pasireotide in normal and tumoral primary pituitary cell culturesAlejandro Ibáñez‐Costa, Raúl M. Luque, Manuel D. Gahete et al.|Endocrine Abstracts|2014Cited by 0
The dopastatin BIM-23A760 distinctly influences key functional endpoints in different types of pituitary adenomas and normal pituitaries: role of somatostatin and dopamine receptor profileJusto P. Castaño, Raúl M. Luque, Alejandro Ibáñez‐Costa et al.|Endocrine Abstracts|2015Cited by 0